Naoto Ueno, MD, PhD, University of Hawai’i Cancer Center, Honolulu, HI, discusses the lack of biomarker-based personalization in HER2-low breast cancer beyond evaluating HER2 status through immunohistochemical staining, as done in studies including the DESTINY-Breast04 trial (NCT03734029). Future analyses may pave the way for more personalized treatment approaches. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
